IMNN Stock Summary and Trading Ideas (Imunon | NASDAQ:IMNN)

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Imunon trades on the NASDAQ stock market under the symbol IMNN.

As of June 5, 2026, IMNN stock price declined to $2.06 with 43,582 million shares trading.

IMNN has a beta of 0.47, meaning it tends to be less sensitive to market movements. IMNN has a correlation of 0.00 to the broad based SPY ETF.

IMNN has a market cap of $8.66 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, IMNN traded as high as $41.40 and as low as $2.04.

The top ETF exchange traded funds that IMNN belongs to (by Net Assets): VXF.

IMNN has underperformed the market in the last year with a price return of -87.0% while the SPY ETF gained +25.6%. IMNN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.3% and -6.4%, respectively, while the SPY returned +8.5% and -1.1%, respectively.

IMNN support price is $1.98 and resistance is $2.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNN shares will trade within this expected range on the day.